Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Research

Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population

Authors: Amit Kumar Mitra, Neetu Singh, Vivek Kumar Garg, Rashmi Chaturvedi, Mandira Sharma, Srikanta Kumar Rath

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

Non-synonymous single nucleotide polymorphisms (SNPs) within vital DNA repair genes may cause reduction of activity leaving the genome unrepaired resulting in genomic instability and cancer.

Materials and methods

The present endeavour involved study on the association of the SNP rs13181 (Lys751Gln/A18911C) in the Nucleotide Excision Repair (NER) pathway gene ERCC2 (excision repair cross-complementing rodent repair deficiency, complementation group 2) with the risks of Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer using a case-control based association study among 685 (400 controls and 285 SCCHN-affected cases) and 395 (227 normal healthy female controls and 168 breast cancer cases) ethnically-matched samples, respectively from north India using Polymerase Chain Reaction followed by Restriction Fragment Length Polymorphism (PCR-RFLP) analysis.

Results

Results showed significant association of rs13181 homozygous mutant (CC) [Odds Ratio (OR) 4.412, 95% Confidence Interval (CI) 2.413 to 8.068], heterozygous (AC) (OR 2.086, 95% CI 1.246 to 3.492) and combined mutant (AC + CC) (OR 2.672, 95% CI 1.647 to 4.334) genotypes with predisposition to Breast cancer. Statistically significant increase in SCCHN risk was also associated with the mutant genotypes of rs13181 (ERCC2), viz. homozygous mutant (CC) (OR 1.680, 95% CI 1.014 to 2.784), heterozygous (AC) (OR 1.531, 95% CI 1.092 to 2.149) and combined mutant (AC + CC) (OR 1.560, 95% CI 1.128 to 2.158) genotypes.

Conclusion

The results of this case-control study indicate that the polymorphism rs13181 might be a risk factor for predisposition towards SCCHN and breast cancer among north Indian subpopulations.
Literature
1.
Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature. 2001, 411: 366-374. 10.1038/35077232.CrossRef
2.
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51: 6304-6311.
3.
Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D: Identification of FAP locus genes from chromosome 5q21. Science. 1991, 253: 661-665. 10.1126/science.1651562.CrossRef
4.
Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48: 5358-5362.
5.
Szabo CI, King MC: Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997, 60: 1013-1020.
6.
Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La VC: Selected medical conditions and risk of breast cancer. Br J Cancer. 1997, 75: 1699-1703.CrossRef
7.
Whiteman DC, Valery P, McWhirter W, Green AC: Risk factors for childhood melanoma in Queensland, Australia. Int J Cancer. 1997, 70: 26-31. 10.1002/(SICI)1097-0215(19970106)70:1<26::AID-IJC4>3.0.CO;2-8.CrossRef
8.
Borish ET, Cosgrove JP, Church DF, Deutsch WA, Pryor WA: Cigarette tar causes single-strand breaks in DNA. Biochem Biophys Res Commun. 1985, 133: 780-786. 10.1016/0006-291X(85)90972-6.CrossRef
9.
Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993, 54: 594-606. 10.1002/ijc.2910540413.CrossRef
10.
Blot WJ, Chow WH, McLaughlin JK: Tea and cancer: a review of the epidemiological evidence. Eur J Cancer Prev. 1996, 5: 425-438.
11.
Dumitrescu RG, Cotarla I: Understanding breast cancer risk – where do we stand in 2005?. J Cell Mol Med. 2005, 9: 208-221. 10.1111/j.1582-4934.2005.tb00350.x.CrossRef
12.
Bohr VA: DNA repair fine structure and its relations to genomic instability. Carcinogenesis. 1995, 16: 2885-2892. 10.1093/carcin/16.12.2885.CrossRef
13.
Ma L, Hoeijmakers JH, Eb van der AJ: Mammalian nucleotide excision repair. Biochim Biophys Acta. 1995, 1242: 137-163.
14.
Radman M, Matic I, Halliday JA, Taddei F: Editing DNA replication and recombination by mismatch repair: from bacterial genetics to mechanisms of predisposition to cancer in humans. Philos Trans R Soc Lond B Biol Sci. 1995, 347: 97-103. 10.1098/rstb.1995.0015.CrossRef
15.
Tlsty TD, Briot A, Gualberto A, Hall I, Hess S, Hixon M, Kuppuswamy D, Romanov S, Sage M, White A: Genomic instability and cancer. Mutat Res. 1995, 337: 1-7.CrossRef
16.
Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q: Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 1998, 7: 465-468.
17.
Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BA, Pharoah PD, Dunning A: Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002, 11: 1399-1407. 10.1093/hmg/11.12.1399.CrossRef
18.
Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM: Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1054-1064.
19.
Shen MR, Jones IM, Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998, 58: 604-608.
20.
Clarkson SG, Wood RD: Polymorphisms in the human XPD (ERCC2) gene, DNA repair capacity and cancer susceptibility: an appraisal. DNA Repair (Amst). 2005, 4: 1068-1074. 10.1016/j.dnarep.2005.07.001.CrossRef
21.
Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vineis P: XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis. 2001, 22: 1437-1445. 10.1093/carcin/22.9.1437.CrossRef
22.
Pachkowski BF, Winkel S, Kubota Y, Swenberg JA, Millikan RC, Nakamura J: XRCC1 genotype and breast cancer: functional studies and epidemiologic data show interactions between XRCC1 codon 280 His and smoking. Cancer Res. 2006, 66: 2860-2868. 10.1158/0008-5472.CAN-05-3388.CrossRef
23.
Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC: Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis. 2001, 22: 593-597. 10.1093/carcin/22.4.593.CrossRef
24.
Sancar A: Excision repair in mammalian cells. J Biol Chem. 1995, 270: 15915-15918.CrossRef
25.
Benhamou S, Sarasin A: ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol. 2005, 161: 1-14. 10.1093/aje/kwi018.CrossRef
26.
Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, Grossman L, Mohrenweiser H, Wei Q: Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis. 2002, 23: 295-299. 10.1093/carcin/23.2.295.CrossRef
27.
Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001, 61: 1354-1357.
28.
Au WW, Salama SA, Sierra-Torres CH: Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect. 2003, 111: 1843-1850.CrossRef
29.
Au WW, Navasumrit P, Ruchirawat M: Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health. 2004, 207: 301-313. 10.1078/1438-4639-00294.CrossRef
30.
Costa S, Pinto D, Pereira D, Vasconcelos A, fonso-Lopes C, Osorio T, Lopes C, Medeiros R: Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer. Cancer Lett. 2007, 246: 324-330. 10.1016/j.canlet.2006.03.014.CrossRef
31.
Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA: XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000, 21: 551-555. 10.1093/carcin/21.4.551.CrossRef
32.
Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, Grossman L, Harris CC: Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res. 2001, 61: 7430-7434.
33.
Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000, 92: 1764-1772. 10.1093/jnci/92.6.440.CrossRef
34.
Benhamou S, Sarasin A: ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002, 17: 463-469. 10.1093/mutage/17.6.463.CrossRef
35.
Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, Miike R, Chen P, Wrensch MR: Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev. 2001, 10: 355-360.
36.
Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M: Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000, 9: 843-847.
37.
Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1513-1530.
38.
Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, Hemminki K: The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis. 2002, 23: 599-603. 10.1093/carcin/23.4.599.CrossRef
39.
Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, Vollmert C, Illig T, Ko YD, Bruning T, Brauch H: ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev. 2004, 13: 2059-2064.
40.
Liang G, Xing D, Miao X, Tan W, Yu C, Lu W, Lin D: Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer. 2003, 105: 669-673. 10.1002/ijc.11136.CrossRef
41.
Mort R, Mo L, McEwan C, Melton DW: Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer. 2003, 89: 333-337. 10.1038/sj.bjc.6601061.CrossRef
42.
Sancar A, Tang MS: Nucleotide excision repair. Photochem Photobiol. 1993, 57: 905-921. 10.1111/j.1751-1097.1993.tb09233.x.CrossRef
43.
Sobti RC, Singh J, Kaur P, Pachouri SS, Siddiqui EA, Bindra HS: XRCC1 codon 399 and ERCC2 codon 751 polymorphism, smoking, and drinking and risk of esophageal squamous cell carcinoma in a North Indian population. Cancer Genet Cytogenet. 2007, 175: 91-97. 10.1016/j.cancergencyto.2007.01.001.CrossRef
44.
Sturgis EM, Zheng R, Li L, Castillo EJ, Eicher SA, Chen M, Strom SS, Spitz MR, Wei Q: XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis. 2000, 21: 2219-2223. 10.1093/carcin/21.12.2219.CrossRef
45.
Tang D, Cho S, Rundle A, Chen S, Phillips D, Zhou J, Hsu Y, Schnabel F, Estabrook A, Perera FP: Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res Treat. 2002, 75: 159-166. 10.1023/A:1019693504183.CrossRef
46.
Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, Sison JD, Aldape K, McMillan A, Wiemels J, Wiencke JK: ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol. 2005, 7: 495-507. 10.1215/S1152851705000037.CrossRef
47.
Xing D, Qi J, Miao X, Lu W, Tan W, Lin D: Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer. 2002, 100: 600-605. 10.1002/ijc.10528.CrossRef
48.
Xing D, Tan W, Wei Q, Lin D: Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer. 2002, 38: 123-129. 10.1016/S0169-5002(02)00184-8.CrossRef
49.
Malhotra KC: Morphological composition of the people of India. J Hum Evol. 1978, 7: 45-63. 10.1016/S0047-2484(78)80035-9.CrossRef
50.
Gadgil M, Joshi NV, Prasad UV, Manoharan S, Patil S: In the Indian human heritage. 1998, Universities Press; Hyderabad, 100-129.
51.
Egly JM: The 14th Datta Lecture. TFIIH: from transcription to clinic. FEBS Lett. 2001, 498: 124-128. 10.1016/S0014-5793(01)02458-9.CrossRef
52.
Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001, 1: 22-33. 10.1038/35094000.CrossRef
53.
Leadon SA, Cooper PK: Preferential repair of ionizing radiation-induced damage in the transcribed strand of an active human gene is defective in Cockayne syndrome. Proc Natl Acad Sci USA. 1993, 90: 10499-10503. 10.1073/pnas.90.22.10499.CrossRef
54.
Satoh MS, Jones CJ, Wood RD, Lindahl T: DNA excision-repair defect of xeroderma pigmentosum prevents removal of a class of oxygen free radical-induced base lesions. Proc Natl Acad Sci USA. 1993, 90: 6335-6339. 10.1073/pnas.90.13.6335.CrossRef
55.
Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM: Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998, 20: 184-188. 10.1038/2491.CrossRef
56.
Brewster AM, Jorgensen TJ, Ruczinski I, Huang HY, Hoffman S, Thuita L, Newschaffer C, Lunn RM, Bell D, Helzlsouer KJ: Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res Treat. 2006, 95: 73-80. 10.1007/s10549-005-9045-3.CrossRef
57.
Dufloth RM, Costa S, Schmitt F, Zeferino LC: DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil. Genet Mol Res. 2005, 4: 771-782.
58.
Metsola K, Kataja V, Sillanpaa P, Siivola P, Heikinheimo L, Eskelinen M, Kosma VM, Uusitupa M, Hirvonen A: XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study. Breast Cancer Res. 2005, 7: R987-R997. 10.1186/bcr1333.CrossRef
59.
Shi Q, Wang LE, Bondy ML, Brewster A, Singletary SE, Wei Q: Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis. 2004, 25: 1695-1700. 10.1093/carcin/bgh167.CrossRef
60.
Bernard-Gallon D, Bosviel R, Delort L, Fontana L, Chamoux A, Rabiau N, Kwiatkowski F, Chalabi N, Satih S, Bignon YJ: DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer. 2008, 7: 36-10.1186/1476-4598-7-36.CrossRef
61.
Terry MB, Gammon MD, Zhang FF, Eng SM, Sagiv SK, Paykin AB, Wang Q, Hayes S, Teitelbaum SL, Neugut AI, Santella RM: Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004, 13: 2053-2058.
62.
Ramachandran S, Ramadas K, Hariharan R, Rejnish KR, Radhakrishna PM: Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol. 2006, 42: 350-362. 10.1016/j.oraloncology.2005.08.010.CrossRef
Metadata
Title
Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population
Authors
Amit Kumar Mitra
Neetu Singh
Vivek Kumar Garg
Rashmi Chaturvedi
Mandira Sharma
Srikanta Kumar Rath
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-104

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue

Research

Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers

Case report

Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports

Research

A study on the functions of ubiquitin metabolic system related gene FBG2 in gastric cancer cell line

Research

The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells

Review

Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease

Research

Development of a novel small antibody that retains specificity for tumor targeting
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits